Athira Pharma Files Definitive Proxy Statement
Ticker: LONA · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 1620463
| Field | Detail |
|---|---|
| Company | Athira Pharma, INC. (LONA) |
| Form Type | DEF 14A |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, regulatory-filing
Related Tickers: ATHA
TL;DR
Athira Pharma (ATHA) filed its proxy statement for the May 29th meeting. No fee paid.
AI Summary
Athira Pharma, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 14, 2025, for its annual meeting on May 29, 2025. The company, formerly known as M3 Biotechnology, Inc., is a biotechnology firm focused on biological products. The filing indicates no fee was required for this filing.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming annual meeting, influencing corporate governance and strategic decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information.
Key Numbers
- 20250529 — Annual Meeting Date (Date of the shareholder meeting for which the proxy statement is filed.)
- 20250414 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Athira Pharma, Inc. (company) — Registrant
- M3 Biotechnology, Inc. (company) — Former company name
- 0001140361-25-013769 (filing_id) — Accession Number
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit shareholder votes for their annual meetings, providing details on proposals, director nominees, and executive compensation.
When is Athira Pharma's annual meeting scheduled?
Athira Pharma's annual meeting is scheduled for May 29, 2025, as indicated by the 'CONFORMED PERIOD OF REPORT' in the filing.
What was Athira Pharma's former name?
Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc., with a date of name change on September 24, 2014.
Was there a filing fee associated with this DEF 14A?
No, the filing explicitly states 'No fee required' under the 'Payment of Filing Fee' section.
What is Athira Pharma's primary business classification?
Athira Pharma, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code [2836].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 regarding Athira Pharma, Inc. (LONA).